Dr. Anke Caßing

Principal / Authorized Signatory

Dr. Anke Caßing has many years of experience in strategic marketing and business development in medical technology, biotechnology and in pharmaceutics. She holds a doctorate in biology and studied economics. Before joining the HTGF, she developed the product portfolios of international companies ensuring their future growth.

Portfolio

Exit

Posts & mentions

Press

14. June 2023

Successful Exit for HTGF: FARCO-PHARMA acquires MedTech Startup Purenum GmbH

Cologne, 14 June 2023: FARCO-PHARMA, a company of the Klosterfrau Healthcare Group, is acquiring Purenum GmbH, which was founded in 2017. The MedTech start-up will operate as a wholly owned subsidiary of FARCO-PHARMA and will continue to drive forward its work in the area of research & development. The seed investor High-Tech Gründerfonds (HTGF), the investment company of BAB - Die Förderbank and FRIBA Investment have closely supported Purenum GmbH since 2018 and are selling their shar

Blog

12. January 2023

MedTech Pitch Day 2023: Connecting Startups with Industry Leaders, Investors, and Decision-Makers

The MedTech Pitch Day, organised by HTGF, Dräger, B.Braun, Techniker Krankenkasse and the Health Innovation Port, is just around the corner. What can founders expect at the event and why should they definitely apply? We spoke to Anke Cassing, Principal at HTGF, and Jakob Lilienweiss, Investment Analyst at HTGF, to find out. The MedTech Pitch Day will take place on March 29th in Berlin. Can you tell us more about the event and what founders can expect? Anke: The event has develop

Blog

12. January 2023

Start-up stories: From science to business

Their first pitch deck didn’t contain a business slide. And there wasn’t any information on market potential. These were things that Dr Isabel Schellinger and Dr Uwe Raaz simply hadn’t thought of. After all, their focus was on their research, on the amazing opportunities made possible thanks to science, and on a medical solution to an aortic disorder in humans that they had developed. This is their passion and their field of expertise. Pitching to investors and founding a start-up were

Press

17. February 2022

Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics

COPENHAGEN, DENMARK, Jan 17th, 2022 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a Seed 2 funding of 3.2 million Euro. The Round was led by Danish Megatrend Invest a/s with strong support from other prior investors including Verve Ventures, a Swiss Investment group and Sanner Ventures, a German family office. Evonik Venture Capital participated as a new investor. Ev

Press

31. January 2022

Dräger AG Invests in Digital Health Startup GWA Hygiene

Lübeck and Stralsund, Germany, 31st of January 2022 – International leader in medical and safety technology, Dräger AG (Lübeck, Germany) and digital health startup GWA Hygiene (Stralsund, Germany) announced today that Dräger will become GWA Hygiene’s newest investor. GWA Hygiene has developed an electronic monitoring system for hand hygiene in hospitals. Before the current financing round, it attracted investments from other well-known funders in Germany, including venture capital fi

Press

11. January 2022

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs  

Hennigsdorf, January 11, 2022 - Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).   ARDS causes a life-threatening damage to the lungs induced by an

Blog

14. December 2021

Post-merger integration as a key factor for successful acquisitions

An acquisition is far from over with the signing of a contract – what then follows is the important process of integration. This is why High-Tech Gründerfonds (HTGF) is offering a think tank on this topic at the High-Tech Partnering Conference in February. The aim of the think tank is to discuss the topic with experts from different viewpoints. In this interview, Anke Caßing and Axel Nitsch, both princip

Press

7. December 2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investorsLead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicityStrategy is to become a dominant ADC developer Duisburg, Germany, 7 December 2021 - Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million series A financing round. T